Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.

@article{Mangia2008IndividualizedTD,
  title={Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.},
  author={A Mangia and Nicola Minerva and Donato Bacca and Raffaele Cozzolongo and Giovanni Luciano Ricci and Vito Carretta and Francesco Vinelli and Gaetano Scotto and Giuseppe Montalto and M{\'a}rio Romano and Giuseppe Cristofaro and Leonardo Mottola and Fulvio Spirito and Angelo Andriulli},
  journal={Hepatology},
  year={2008},
  volume={47 1},
  pages={43-50}
}
UNLABELLED It was hypothesized that in hepatitis C virus (HCV) genotype 1 patients, variable treatment duration individualized by first undetectable HCV RNA is as effective as standard 48-week treatment. Patients (n = 696) received peginterferon alfa-2a, 180 mg/week, or peginterferon alfa-2b, 1.5 mg/kg/week, plus ribavirin, 1000-1200 mg/day, for 48 weeks (standard, n = 237) or for 24, 48, or 72 weeks if HCV-RNA-negative at weeks 4, 8, or 12, respectively (variable, n = 459). Sustained virologic… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS